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Background: The aim of this study was to examine the measurement properties of the Dutch SF-36 version 2
(SF-36v2) health survey in patients with rheumatoid arthritis (RA).
Methods: Scaling assumptions, internal reliability, and internal construct validity were examined using available
data from 1884 RA patients included in the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. External
construct validity and responsiveness to change were examined using baseline and 6-month follow-up data from a
subset of 387 early RA patients participating in the DREAM remission induction cohort.
Results: The individual items of the SF-36v2 adequately met scaling assumptions, although four items correlated
too highly with items from different scales. Internal consistency was high for all eight scales and the physical and
mental health components underlying the scales were replicated, supporting the use of the standard scoring
algorithms. The SF-36v2 scales demonstrated minimal floor effects and ceiling effects were noteworthy only for
the role-physical, social functioning, and role-emotional scales. Correlations with other core measures were as
expected and the SF-36v2 showed excellent known-groups validity in distinguishing between patients with low or
moderate-high disease activity. All scales related to physical health showed moderate to large responsiveness to
change in patients that achieved low disease activity at six months.
Conclusion: The SF-36v2 appears to be a psychometrically sound tool for the assessment of health-related quality
of life of Dutch patients with RA.Background
Health-related quality of life (HRQOL) questionnaires are
increasingly used to measure the impact of disease and the
effects of treatment from the perspective of the patient. A
well-known questionnaire for the assessment of HRQOL is
the 36-Item Short-Form (SF-36) Health Survey [1]. The
SF-36 is a multidimensional questionnaire that assesses
eight different aspects of health. It is generic by nature
which means that it, as opposed to disease-specific mea-
sures, can be used to measure and compare outcomes
across different diseases and treatments. This feature has
made generic measures of HRQOL increasingly popular
among researchers and clinicians and the SF-36 has* Correspondence: P.M.tenKlooster@utwente.nl
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distribution, and reproduction in any mediumbecome the most frequently used measure across a wide
range of range of conditions, including rheumatic diseases
[2,3]. A review of patient-reported outcomes in recently
published rheumatoid arthritis (RA) trials [4] showed that
the SF-36 was used in 80% of the studies that reported
the use of a HRQOL measure, while traditional disease-
specific measures were used much less frequently.
The SF-36 has been extensively validated for use in both
general and condition-specific populations in many lan-
guages and countries, including several studies in patients
with RA [5-10]. These studies have generally shown the
SF-36 to be a psychometrically sound measure of HRQOL
in RA. Although generic measures are often assumed to be
potentially less sensitive in detecting changes over time in
specific diseases [11,12], studies in RA found that the dif-
ferent scales of the SF-36 were as responsive to changesntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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health domains [10,13-15].
In 1996, a new version of the questionnaire (SF-36v2)
was introduced which included improvements in the in-
structions, the wording of some of the items, and the num-
ber of response options for two of the eight scales [16,17].
Several general population studies have confirmed the im-
proved precision, reliability, and validity of the SF-36v2 over
the original version [18,19]. To date, however, the psycho-
metric properties of the SF-36v2 have not yet been thor-
oughly validated in RA patients. Therefore, the objective of
this study was to examine the scaling assumptions, reliabil-
ity, construct validity, and responsiveness of the SF-36v2 in
a clinically diverse sample of Dutch patients with RA.Methods
Patients and study design
Data for this study were derived from the Dutch Rheuma-
toid Arthritis Monitoring (DREAM) registry. The DREAM
registry is an observational multicenter cohort study that
monitors the course of RA patients undergoing different
treatment regimens in the Netherlands [20]. Clinical, la-
boratory, and patient-reported outcomes are routinely col-
lected and stored. Patient-reported outcomes are generally
completed online. Within DREAM, 1884 unique patients
from different hospital rheumatology clinics completed the
SF-36v2 at least once. For the assessment of scaling proper-
ties and internal reliability and construct validity, the most
recently completed SF-36v2 was selected from each patient,
resulting in a sample of 1884 RA patients that completed
the SF-36v2 between March 2005 and December 2012. The
majority of the sample was female (64.0%) and mean (SD)
age and disease duration of the patients at the time of com-
pletion were 58.3 (13.2) and 4.2 (7.6) years, respectively.
External construct validity and the responsiveness to
change of the SF-36v2 were examined in a subset of early
RA patients participating in the DREAM remission induc-
tion cohort [21]. The remission induction cohort consists
of patients with early RA participating in a treat-to-target
strategy aimed at achieving fast remission. The strategy has
been shown to be highly effective, with the largest im-
provement in disease activity observed in the first 6
months of treatment [21]. Baseline and 6-month follow-up
SF-36v2 data were available from 387 patients. Similar to
the total DREAM sample, 62.4% of the patients in this sub-
set was female and the mean age at baseline of the patients
was 58.6 (14.1) years. Median symptom duration at base-
line was 14.0 weeks.
The study protocol for the DREAM registry was submit-
ted to the ethics committee of each participating hospital.
Because the DREAM registry collects data for daily clinical
practice, the ethics committees determined, in accor-
dance with Dutch law, that no approval was required.Nonetheless, patients were fully informed and informed
consent was obtained.
Measures
The standard 4-week recall Dutch version of the SF-36v2
(QualityMetric Inc.) was used, which was developed using
an extensive translation process which has its origins in the
International Quality of Life Assessment (IQOLA) project
approach [16,22]. This translation process consists of mul-
tiple forward and backward translations and cognitive
debriefing interviews with native speakers of the target
language. The SF-36v2 assesses different aspects of health
represented in 8 scales: physical functioning (PF: 10 items),
bodily pain (BP: 2 items), social functioning (SF: 2 items),
mental health (MH: 5 items), general health (GH: 5
items), vitality (VT: 4 items), role physical (RP: 4 items),
and role emotional (RE: 3 items) [16,17]. The PF items
were intended to constitute a hierarchical Guttman scale,
in which each item consistently decreases in severity or dif-
ficulty. All items are rated on Likert-type or frequency re-
sponse scales, ranging from 3 response categories for the
PF items to 6 categories for a BP item. Using the standard
scoring algorithm [17], scales scores are linearly trans-
formed to range from 0 to 100, with higher scores
representing better health status. Additionally, the scale
scores can be aggregated into two distinct (orthogonal)
higher-order summary scores: a physical component sum-
mary (PCS) and a mental component summary (MCS).
The component summary scores are standardized using
normative data from the 1998 US general population with
a mean score of 50 and a standard deviation of 10.
Beside the SF-36v2, several simultaneously collected clin-
ical and patient-reported variables were used for analyses
in the remission induction cohort sample. For all patients,
disease activity was calculated using the Disease Activity
Score 28 (DAS28) [23]. The DAS28 combines a 28 swollen
joint count, a 28 tender joint count, the erythrocyte sedi-
mentation rate (ESR), and a patient global assessment
(PGA) of well-being on a visual analog scale into an overall
continuous index. Total scores range between 0 and 10,
with higher scores indicating higher disease activity. Vali-
dated cutoff scores have been defined for low disease activ-
ity (≤3.2), moderate disease activity (3.2-5.1) and high
disease activity (>5.1) [24]. Patient-reported disability was
measured with the Health Assessment Questionnaire Dis-
ability Index (HAQ-DI) on a scale from 0 to 3, in which
higher scores indicate more disability [25,26].
Statistical analyses
All analyses were performed using IBM SPSS Statistics ver-
sion 20. Scaling assumptions and internal reliability of the
SF-36v2 were examined in the first dataset (N = 1884) fol-
lowing the approach of the International Quality of Life
Assessment project [27]. First, item-level descriptive
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Next, correlations of each item with its own scale as well
as with other scales were examined using a multi-trait/
multi-item correlation matrix approach. For each scale,
item internal consistency was considered satisfactory if
items correlated ≥0.40 with their own scale after correction
for item-scale overlap. Item discriminant validity was
supported when an item correlated significantly higher
(≥2 standard errors) with its own scale than with the other
scales. Scaling success rates were calculated as the
percentage of item scaling tests passed.
The reliability of the scales was calculated with Cron-
bach’s coefficient α and considered adequate for group-level
and person-level comparisons when ≥0.70 and ≥0.90,
respectively.
To test the internal construct validity of the scales and
the hypothesized physical and mental dimensions of health
underlying these scales, 0–100 transformed scale scores
were computed and the pattern of correlations between
the eight scales was examined. It was hypothesized that
scales that were conceptually related (physical or mental
health, respectively) would correlate substantially (r ≥0.40).
High correlations (>0.70) were considered undesirable be-
cause this would question the distinctiveness of the scales.
Further, the scale’s reliability estimates should be greater
than the correlations with the other scales.
To examine the plausibility of the physical and mental
dimensions, a principal component analysis with varimax
rotation was performed. Two components were extracted,
and the scale’s correlations with the rotated factors were
examined [28]. Based on the measurement model of the
SF-36 [16,17], the PF, RP, and BP scales were hypothesized
to correlate most highly with the physical component and
lowest with the mental component, whereas the MH, RE,
and SF scales should correlate most highly with the mental
component and lowest with the physical component. The
GH and VT scales were expected to show substantial cor-
relations with both components and the SF scale was
expected to show a substantial cross-loading on the phys-
ical component.
External construct validity and responsiveness were ex-
amined using the 6-month data of patients participating in
the remission induction cohort. External construct validity
was examined by means of convergent/discriminant valid-
ity and known-groups validity [29]. For convergent/dis-
criminant validity it was expected that the SF-36v2 scales
related to physical health would be associated moderately
(r ≥0.30) to strongly (r ≥0.60) with disability and well-
being, moderately with the tender joint count, and weakly
(r <0.30) or not at all with the swollen joint count and ESR.
Overall, a similar hierarchy of weaker asso-ciations was
expected for the GH and VT scales and mental scales. For
known-groups validity it was examined whether the SF-
36v2 was able to distinguish between patients with low(DAS28 ≤3.2) and moderate to high levels of disease activ-
ity. One-way analysis of variance (ANOVA) was employed
to test for the statistical significance of group differences.
The physical scales and PCS were expected to be most
discriminative.
Responsiveness [30] of the scales and component scores
was examined by their ability to detect changes between
baseline and 6-month follow-up using paired t-tests. To
examine the magnitude of change, standardized response
means (SRMs) were calculated as the ratio of the mean
change to the SD of that change for all scores in both the
total sample and separately for patients who did or did not
achieve low disease activity. Values of 0.20, 0.50, and 0.80
or greater were considered small, medium, and large, re-
spectively [31]. Bootstrapping with 1000 samples was
applied to obtain 95% confidence intervals (CIs) for the
SRMs.
Results
Item-level descriptive statistics
The median time needed to complete the SF-36v2 was 5
minutes. The full range of responses to each item was ob-
served (Additional file 1: Table S1). Item means clustering
and ordering were comparable to those of the general
population [17] and items within each scale had similar
standard deviations. Mean item scores, especially for items
addressing physical health, were generally lower than those
in the general population. More difficult PF items generally
had higher mean scores, confirming the Guttman-type
properties of this scale.
Scaling assumptions
Corrected correlations between the items and their hy-
pothesized scales ranged from 0.36 to 0.91 (Additional file
2: Table S2). Except for one VT item (item 9a), all items
passed the test for item internal consistency with correla-
tions between the items and their scales ≥0.40 (Table 1).
Additionally, all items from the RP, BP, RE, and MH scales
passed the test for item discriminant validity with signifi-
cantly higher correlations between the items and their
scales than with the other scales. The other four scales all
had one item that failed one or more scaling tests.
Reliability and internal construct validity
Reliability estimates ranged from 0.79 for GH and VT to
0.95 for RP, exceeding the 0.70 standard for group compari-
sons for all scales and the 0.90 standard for individual com-
parisons for three scales (Table 2). Correlations between
the scales ranged from 0.37 (PF and MH) to 0.71 (PF and
RP), the latter being the only correlation exceeding the 0.70
limit for distinctiveness. Generally, the highest correlations
between scales were observed between scales within either
the physical or mental dimension, although several correla-
tions between scales from the different dimensions were
Table 1 Scaling assumptions of the SF-36v2 (N = 1884)
Range of correlations Item scaling tests
Scales ka Item internal consistencyb Item discriminant validityc Item internal consistencyd Item discriminant validitye
PF 10 0.58 to 0.79 0.24 to 0.64 10/10 (100%) 69/70 (98.6%)
RP 4 0.84 to 0.90 0.43 to 0.68 4/4 (100%) 28/28 (100%)
BP 2 0.81 0.36 to 0.70 2/2 (100%) 14/14 (100%)
GH 5 0.48 to 0.68 0.26 to 0.60 5/5 (100%) 31/35 (88.6%)
VT 4 0.36 to 0.69 0.22 to 0.62 3/4 (75%) 27/28 (96.4%)
SF 2 0.70 0.50 to 0.66 2/2 (100%) 13/14 (92.9%)
RE 3 0.86 to 0.91 0.39 to 0.64 3/3 (100%) 21/21 (100%)
MH 5 0.64 to 0.76 0.25 to 0.62 5/5 (100%) 35/35 (100%)
aNumber of items; bPearson correlations between items and hypothesized scales corrected for overlap (correlation with the sum of the other items in the same
scale); cPearson correlations between items and other scales; dNumber (%) of items out of k with correlation ≥ 0.40; eNumber (%) of items out of 7xk where the
difference between the corrected correlation of the item with its own scale and correlation with the other scales ≥ 2SE (= 0.046). PF = Physical Functioning; RP,
Role-physical; BP, Bodily pain; GH, General health; VT, Vitality; SF, Social functioning; RE, Role-emotional; MH, Mental health; HT, Health transition.
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themselves (Cronbach’s α) than with the other scales.
In the principal component analysis, the two factors
explained 73.45% of the variance. Correlations between the
scales and their rotated components confirmed the meas-
urement model of the SF-36v2. As shown in Table 2, the
physical scales had clearly higher correlations with the
physical component (range: 0.78-0.84) than with the mental
component (range: 0.19-0.42). The mental scales showed
the opposite pattern (range of correlations with physical
component: 0.18-0.58, range of correlations with mental
component 0.63-0.91). GH and VT correlated substantially
with both components, although the latter correlated more
strongly with the physical component and less strongly with
the mental component than expected. In accordance with
the measurement model, the SF scale demonstrated a note-
worthy cross-loading on the physical component.
Statistics for scales and summary scores
Table 3 summarizes descriptive statistics and features of
scale score distributions for the eight SF-36v2 scales andTable 2 Pearson correlations between the SF-36v2 scales, inte
rotated factor components (N = 1884)
Observed correlations
Scales PF RP BP GH VT SF RE
PF (0.93)
RP 0.71 (0.95)
BP 0.63 0.69 (0.88)
GH 0.54 0.60 0.54 (0.79)
VT 0.57 0.67 0.60 0.62 (0.79)
SF 0.58 0.68 0.61 0.56 0.67 (0.82)
RE 0.47 0.64 0.45 0.46 0.55 0.61 (0.94)
MH 0.37 0.49 0.40 0.46 0.63 0.63 0.65 (0
Scale internal consistency reliability (Cronbach’s α) is presented in the diagonal. PF,
Vitality; SF, Social functioning; RE, Role-emotional; MH, Mental health; P, Physical faccomponent summaries. The full range of the score distri-
bution was observed for all scales. Scores tended to be
negatively skewed for the scales measuring mental health
(SF, RE, and MH), indicating distributions with more pa-
tients scoring among the more positive health states. Floor
effects were negligible for all scales but notable ceiling ef-
fects were observed for the SF and RE scales, although
these ceiling effects were less pronounced than in the gen-
eral population [17], The mean PCS was almost one SD
below the general population norm, whereas the MCS
scores were similar to those for the general population.External construct validity
The scales and component summaries demonstrated the
expected pattern of associations with patient-reported
disability and disease activity parameters (Table 4). As
hypothesized, scales related to physical health generally
correlated moderately to strongly with disability and well-
being, moderately with number of tender joints, and
weakly or not at all with the swollen joint count and ESR.rnal consistency estimates, and correlations with the two
Hypothesized Observed correlations
MH Dimension Physical component Mental component
P 0.85 0.19
P 0.78 0.42
P 0.83 0.22
P/M 0.66 0.38
M/P 0.60 0.59
M 0.58 0.63
M 0.33 0.79
.87) M 0.18 0.91
Physical functioning; RP, Role-physical; BP, Bodily pain; GH, General health; VT,
tor content; M, Mental factor content.
Table 3 Descriptive statistics of the transformed SF-36v2 scale scores and normed summary scores (N = 1884)
Scales Range a Mean Median SD Skewness Kurtosis Floor (%)b Ceiling (%)c
PF 0 to 100 64.55 70.00 26.06 −0.53 −0.72 1.1 6.4
RP 0 to 100 57.92 50.00 27.44 −0.02 −0.83 2.5 15.5
BP 0 to 100 61.01 62.00 21.83 −0.09 −0.43 0.5 9.4
GH 0 to 100 54.61 52.00 19.60 0.03 −0.39 0.1 1.1
VT 0 to 100 57.96 56.25 19.54 −0.08 −0.43 0.1 2.1
SF 0 to 100 77.62 87.50 22.76 −0.85 0.07 0.5 35.8
RE 0 to 100 72.98 75.00 27.15 −0.68 −0.50 1.6 37.0
MH 0 to 100 75.92 80.00 17.92 −0.88 0.60 0.1 9.3
PCS d 6 to 65 41.15 41.43 9.85 −0.24 −0.43 - -
MCS d 9 to 77 50.06 52.45 10.68 −0.79 0.26 - -
aObserved scores; bPercentage of respondents with worst possible score; cPercentage of respondents with best possible score; dThe component summary scores
are standardized using normative data from the 1998 US general population with a mean score of 50 and an SD of 10. PF, Physical functioning; RP, Role-physical;
BP, Bodily pain; GH, General health; VT, Vitality; SF, Social functioning; RE, Role-emotional; MH, Mental health; HT, Health transition; PCS, Physical component
summary; MCS, Mental component summary.
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for the mental scales.
Scores on all scales and the components were sig-
nificantly higher for people with low disease activity,
supporting strong known-groups validity of the SF-36v2
(Table 4). The physical scales and PCS were most dis-
criminative. The PF scale performed somewhat worse than
the disease-specific HAQ-DI, which obtained an F-value
of 84.55 in distinguishing between the disease activi-
ty groups.
Responsiveness to change
Mean scores on the DAS28 improved from 4.42 (1.47) at
baseline to 2.73 (1.15) after six months. All eight scalesTable 4 Convergent/discriminant validity and known-groups
scores (N = 387)
Spearman correlations at 6 month
HAQ-DI PGA TJC SJC ESR
(n = 378) (n = 338) (n = 338) (n = 338) (n = 337)
PF −0.76 −0.49 −0.36 −0.17 −0.13
RP −0.58 −0.54 −0.32 −0.19 0.02
BP −0.64 −0.65 −0.44 −0.29 −0.09
GH −0.43 −0.46 −0.24 −0.05 −0.08
VT −0.47 −0.47 −0.21 −0.06 −0.05
SF −0.51 −0.45 −0.24 −0.10 −0.01
RE −0.47 −0.44 −0.13 −0.05 −0.04
MH −0.34 −0.32 −0.13 −0.05 −0.00
PCS −0.71 −0.58 −0.44 −0.24 −0.12
MCS −0.33 −0.34 −0.07 −0.00 −0.05
PF, Physical functioning; RP, Role-physical; BP, Bodily pain; GH, General health; VT, V
transition; PCS, Physical component summary; MCS, Mental component summary; H
assessment of well-being; visual analog scale for general health; TJC, Tender joint coand the PCS significantly improved between baseline
and six months (Table 5). SRMs in the total sample were
moderate for the BP scale and PCS. In the group achiev-
ing low disease activity, SRMs were at least moderate for
all physical scales and large for the BP scale and PCS.
All SRMs were small in the group that did not achieve
low disease activity. The PF scale was slightly less re-
sponsive than the disease-specific HAQ-DI which had
an SRM of 0.56 (95% CI: 0.47 to 0.66) in the total group
and 0.75 (95% CI: 0.62 to 0.88) in the low disease activity
group. However, these differences in SRMs were not sig-
nificant in either the total group (mean difference 0.08;
95% CI: -0.01 to 0.18) or the low disease activity group
(mean difference 0.03; 95% CI: -0.08 to 0.15).validity of the SF-36v2 scales and summary
Mean (SD) scores across levels of disease activity at 6 months
Low disease activity Moderate-high F(1, 331) P
(DAS28 ≤3.2) disease activity
(n = 232) (n = 101)
73.56 (23.29) 52.87 (23.51) 55.18 <0.001
65.46 (26.24) 43.19 (24.18) 53.11 <0.001
70.86 (18.39) 47.58 (17.28) 116.89 <0.001
63.41 (18.46) 48.85 (17.85) 44.60 <0.001
63.47 (19.10) 50.19 (18.51) 34.67 <0.001
83.73 (20.06) 69.93 (22.58) 30.83 <0.001
75.32 (26.20) 58.66 (29.20) 26.52 <0.001
77.84 (17.99) 70.00 (20.00) 12.49 <0.001
45.77 (8.40) 36.48 (7.45) 91.97 <0.001
50.72 (10.51) 46.16 (12.05) 12.07 0.001
itality; SF, Social functioning; RE, Role-Emotional; MH, Mental health; HT, Health
AQ-DI, Health assessment questionnaire disability index; PGA, Patient global
unt; SJC, Swollen joint count; ESR, Erythrocyte sedimentation rate.
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This is the first study to examine the measurement prop-
erties of the generic SF-36v2 in Dutch patients with RA.
The scaling assumptions of the SF-36v2 were generally
supported and the questionnaire demonstrated internal
reliability and internal construct validity similar to those
found in the general US population. The individual scales
and components demonstrated the expected pattern of as-
sociations with patient-reported and clinical outcome
measures and were able to discriminate well between pa-
tients with low and moderate to high levels of disease ac-
tivity. Especially the physical scales were adequately
responsive to changes in disease activity. Overall, the find-
ings suggest that the SF-36v2 is a psychometrically robust
measure of HRQOL in Dutch patients with RA.
Excellent scaling success rates were found for four of
the SF-36 scales (RP, BP, RE, and MH), which corresponds
with findings from the original SF-36 version in the gen-
eral Dutch population and in chronic disease populations
[32]. All items of the SF-36v2 passed the test for item in-
ternal consistency, except for item 9a (Did you feel full of
life?). This item correlated too weakly with the other vital-
ity items and slightly more strongly with the mental health
scale. Although this finding is not too surprising given the
item phrasing, it has not been reported in previous stud-
ies. Given that the overall internal consistency of the vital-
ity scale was acceptable, however, it did not substantially
affect the performance of this scale. The finding that the
overall general health item (item 1) also correlated sub-
stantially with several other scales corresponds with previ-
ous studies in specific patient samples [9,32,33] which also
showed the lowest percentage of scaling successes for item
discriminant validity of the GH scale in these populations.
Despite these deviations, all eight scales met the internalTable 5 Responsiveness of the SF-36v2 scales and summary s
Scales Baseline 6-month
change
P To
Mean (SD) Mean (SD)
PF 57.05 (25.30) 10.10 (21.47) <0.001 0.47
RP 45.45 (27.41) 12.90 (27.01) <0.001 0.47
BP 45.16 (21.10) 18.20 ( 24.61) <0.001 0.76
GH 55.60 (18.30) 2.76 (16.41) 0.001 0.17
VT 53.60 (20.61) 5.56 ( 17.72) <0.001 0.31
SF 70.99 (24.43) 8.04 ( 24.08) <0.001 0.33
RE 66.88 (28.35) 3.47 (26.79) 0.011 0.13
MH 71.62 (19.22) 3.88 (17.68) <0.001 0.22
PCS 37.13 (9.18) 5.62 (8.58) <0.001 0.66
MCS 48.33 (11.64) 0.98 (9.95) 0.052 0.10
PF, Physical functioning; RP, Role-physical; BP, Bodily pain; GH, General health; VT, V
transition; PCS, Physical component summary; MCS, Mental component summary; Sreliability standards required for comparing groups of pa-
tients, and the physical function, role-physical, and role-
emotional scales appear to be suitable for monitoring
individuals.
In general, the observed high percentage of scaling suc-
cesses lends strong support to the hypothesized scale
structure of the SF-36v2 in patients with RA. The internal
construct validity was further supported by the scales’ cor-
relations with the physical and mental components of
health. Principal component analysis supported the exist-
ence of the two hypothesized dimensions underlying the
SF-36v2. Together the two dimensions accounted for a
significant proportion (73.45%) of the reliable variance in
the eight scale scores. The correlations of the scales with
their principal components were as expected and were
fairly similar to the hypothesized measurement model of
the SF-36v2 in the general population [16,17] and those
found for the original SF-36 in previous studies in patients
with RA [7,9].
The vitality scale, however, correlated evenly strong with
both components, whereas it correlated most strongly
with mental health in the general population. Apparently,
vitality is closely related to the other physical problems as-
sociated with RA, such as pain and physical functioning, a
finding that is supported by the recent attention focused
on the issue of increased fatigue in RA [34-36]. Similar
problems with the vitality scale have also been observed in
patients with severe functional somatic syndromes [33]
and in people with ischemic stroke [37]. Other studies
have also challenged the assumption that the way in which
the eight scales relate to the physical and mental compo-
nent is uniform across both diseased and healthy individ-
uals. Findings from these studies generally suggest that
the vitality scale in particular may relate to physical andcores (N = 387)
SRM (95% CI)
tal sample Low disease activity Moderate-high
(DAS28 ≤3.2) disease activity
(n = 232) (n = 101)
(0.37 to 0.58) 0.72 (0.58 to 0.85) 0.19 (0.00 to 0.38)
(0.36 to 0.58) 0.66 (0.53 to 0.79) 0.20 (0.01 to 0.38)
(0.65 to 0.85) 1.07 (0.94 to 1.19) 0.40 (0.22 to 0.58)
(0.05 to 0.27) 0.40 (0.27 to 0.52) −0.21 (0.41 to −0.00)
(0.21 to 0.42) 0.53 (0.39 to 0.66) 0.02 (−0.17 to 0.22)
(0.22 to 0.44) 0.52 (0.39 to 0.65) 0.11 (−0.11 to 0.33)
(0.03 to 0.23) 0.31 (0.18 to 0.44) −0.19 (−0.40 to 0.02)
(0.12 to 0.33) 0.37 (0.23 to 0.50) 0.05 (−0.16 to 0.27)
(0.55 to 0.76) 0.93 (0.80 to 1.07) 0.32 (0.14 to 0.50)
(0.00 to 0.21) 0.26 (0.12 to 0.39) −0.15 (−0.36 to 0.07)
itality; SF, Social functioning; RE, Role-emotional; MH, Mental health; HT, Health
RM, Standardized response mean.
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tient’s main condition is a physical or mental illness [38].
The finding that all other scales were associated with the
two dimensions as expected and the high percentage of
scaling successes for all scales, however, does support the
legitimacy of generating scores for the eight scales and
two summary measures using the standard algorithms.
Moreover, using the standard US-based scoring algorithm,
the PCS and MCS were negligibly correlated (r = 0.16),
further supporting the orthogonal nature of the US-based
component summary scores.
One of the aims of the developers of the SF-36v2 was to
increase the internal reliability and to reduce the floor and
ceiling effects that have been reported in the literature for
the role-emotional and role-physical scales by increasing
the number of response options for these scales from two
to five [16]. The findings in this study suggest that these
scales are indeed more reliable than in the previous version
[16,32] and that especially their floor effects have been
strongly reduced. Both role scales and the social function-
ing scale still demonstrated substantial ceiling effects, al-
though these were much smaller than those observed in
the general population [17,18]. These improvements are
likely to have increased the ability of the SF-36v2 scale to
discriminate between groups and to detect changes over
time as compared with the original version.
The SF-36v2 demonstrated excellent convergent/discrim-
inant and known-groups validity. The DREAM registry
data allowed for a direct comparison of SF-36v2 scores with
simultaneously collected self-reported and clinical core dis-
ease activity parameters [39]. The different scales of the SF-
36v2 correlated as expected with the core measures of
disease activity. All scales were additionally able to distin-
guish between patients with low disease activity and those
with moderate to high disease activity as measured with the
DAS-28. The DAS-28 is currently the standard-of-care
measure of disease activity in RA [40] and the best deter-
minant of the physician’s clinical judgment of response to
treatment [41]. As expected, the physical scales, including
bodily pain, were most discriminative. However, the phys-
ical functioning scale did not perform as well as the HAQ-
DI, which over the years has become the standard measure
of self-reported disability in many rheumatic conditions
[42]. The HAQ-DI was still about 53% more effective in
distinguishing between known groups, a finding similar to
the one recently observed in patients with gout [43].
The finding that the SF-36v2 was able to discriminate
well between patients with low and moderate to high dis-
ease activity, but also to detect improvements over the first
six months of treatment, suggests that it can be useful for
both discriminative and evaluative purposes [11] in patients
with RA. The generic nature of the SF-36v2 additionally of-
fers the opportunity of comparing the HRQOL of RA pa-
tients with those in other rheumatic and non-rheumaticconditions and with general population norms. These ad-
vantages, however, come with a potential loss of responsive-
ness and relevance to specific patient groups [2,11,12].
Nevertheless, in accordance with previous studies examin-
ing the original SF-36 in RA [10,13-15], this study showed
that the generic nature of the SF-36v2 did not result in sub-
stantially reduced responsiveness. Especially the physical
and bodily pain scales showed moderate or large improve-
ments in those patients achieving low disease activity.
Moreover, although the disease-specific HAQ-DI had better
known-groups validity than the physical functioning scale,
it was only slightly and non-significantly more responsive
to improvements over time.
The finding that the SF-36v2 meets psychometric criteria
does not necessarily mean that the questionnaire covers all
issues specifically relevant to patients with RA. For in-
stance, the physical functioning scale of the SF-36v2 mainly
covers functions related to mobility and other activities re-
quiring the use of the lower extremities, whereas finger
function is not captured at all and arm function only by
three items related to daily activities [44]. A recent review
further indicated that the scale has limited content validity
as it has no content relevant to the assessment of domestic
life [45]. Therefore, for a thorough and comprehensive as-
sessment of health-related quality of life the common rec-
ommendation to use both disease-specific and generic
measures if possible [15,46] still holds.
In this light, recent initiatives to integrate and cross-
calibrate generic and disease-specific measures of health-
related quality of life using applications of item response
theory and computerized adaptive testing are particularly
interesting. Based on existing questionnaires, the NIH
Patient-Reported Outcomes Measurement Information
System (PROMIS) project has developed large cali-
brated item banks that can be used to measure key
symptoms and health concepts across a wide variety of
chronic diseases and in the general population [47].
This blended approach is likely to overcome the limita-
tions of the current generation of disease-specific and
generic questionnaires and may allow for more relevant,
precise, and efficient assessment of health status and
comparability of experiences across diseases.
Finally, it should be noted that in the current study sev-
eral comparisons were made with normative data from the
US general population as no Dutch norms are currently
available for version 2 of the SF-36. The US norms, how-
ever, are not necessarily generalizable to other countries or
cultures. Some studies comparing the US norms with those
of other countries have suggested that although the magni-
tude of differences is generally small, for some scales they
are close to or just above the difference of 5 points consid-
ered to be clinically meaningful [48-50].
In conclusion, the SF-36v2 demonstrated adequate
psychometric properties in patients with RA. Using the
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the identification of HRQOL issues and changes in
HRQOL that are important to patients and will facilitate
comparisons across different disease states.
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